Patel Muniraj, Shah Ravikumar, Ramteke-Jadhav Swati, Patil Virendra, Patel Shivendra Kumar, Lila Anurag, Shah Nalini, Bandgar Tushar
Department of Endocrinology, Seth GS Medical College & KEM Hospital, Parel, India.
Ruxamaniben Deepchandra Gardi Medical College, Ujjain, India.
Clin Endocrinol (Oxf). 2020 May;92(5):409-420. doi: 10.1111/cen.14174. Epub 2020 Feb 26.
Awareness about Insulin Autoimmune Hypoglycaemia (IAH) and its management remains limited.
We describe two cohorts: Cohort 1 (n = 7) included patients with IAH from a tertiary care centre in India and Cohort 2 (n = 294) included systematic review of published English literature from PubMed. They were compared with our insulinoma patients (n = 41).
Cohort 1 included seven female patients where two had drugs (carbimazole and thiocolchicoside) as triggering factors. Except for one patient requiring oral prednisolone, others had spontaneous remission. The unique features from our series are being first case series of IAH from India and reporting of second case of thiocolchicoside triggered IAH. Cohort 2 had 294 patients identified from 149 publications. Mean age was 54 ± 19 years. Thirty-five different triggers were identified from 160 cases. Antithyroid drugs were most common triggers in Japanese patients and most common HLA allele was DRB10406, while it was alpha-lipoic acid and HLA DRB10403 in non-Asians. Serum Insulin >100 µIU/mL and insulin to C-peptide molar ratio (ICMR) >0.25 had specificity of 100% and 97.5%, respectively, for IAH as compared to insulinoma. 56% patients had remission with complex carbohydrate diet and trigger removal while 43% required immunosuppressants. 70% achieved remission within 6 months.
Middle age remains most common age group. Sulfhydryl drugs are most common triggers. Serum Insulin >100 µIU/mL and ICMR > 0.25 in critical sample are good predictors for diagnosis of IAH, which needs to be confirmed by IAA. Conservative management with dietary modification and trigger removal usually suffices in majority. Rests need immunosuppressants.
对胰岛素自身免疫性低血糖症(IAH)及其管理的认识仍然有限。
我们描述了两个队列:队列1(n = 7)包括来自印度一家三级护理中心的IAH患者,队列2(n = 294)包括对来自PubMed的已发表英文文献的系统综述。将它们与我们的胰岛素瘤患者(n = 41)进行比较。
队列1包括7名女性患者,其中2名患者的触发因素为药物(卡比马唑和秋水仙硫胺)。除1名患者需要口服泼尼松龙外,其他患者均自发缓解。我们系列的独特之处在于这是印度IAH的首个病例系列,并报告了秋水仙硫胺引发的IAH的第二例病例。队列2从149篇出版物中识别出294名患者。平均年龄为54±19岁。从160例病例中识别出35种不同的触发因素。抗甲状腺药物是日本患者中最常见的触发因素,最常见的HLA等位基因为DRB10406,而在非亚洲人中则是α-硫辛酸和HLA DRB10403。与胰岛素瘤相比,血清胰岛素>100 µIU/mL和胰岛素与C肽摩尔比(ICMR)>0.25对IAH的特异性分别为100%和97.5%。56%的患者通过复合碳水化合物饮食和去除触发因素实现缓解,而43%的患者需要免疫抑制剂。70%的患者在6个月内实现缓解。
中年仍然是最常见的年龄组。巯基药物是最常见的触发因素。关键样本中血清胰岛素>100 µIU/mL和ICMR>0.25是诊断IAH的良好预测指标,这需要通过胰岛素自身抗体(IAA)来确认。大多数情况下,通过饮食调整和去除触发因素的保守管理通常就足够了。其余患者需要免疫抑制剂。